cenegermin: Clinical Trials

6 trials of cenegermin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 withdrawn. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 5, Withdrawn 1
Phase 22Completed 2

Follow cenegermin: new trials by email Literature Review of cenegermin trials Research Report on cenegermin

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NGF Treatment for Patients With Neuropathic Corneal Pain
Cenegermin-Bkbj - Corneal Disease, Neuropathy
Phase 1WithdrawnTufts Medical Center2022-11-012023-01-26
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
rhNGF 20μg/mL, Placebo - Healthy Volunteers
Phase 1CompletedDompé Farmaceutici S.p.A302018-03-302023-12-26
Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
rhNGF, Vehicle - Glaucoma
Phase 1CompletedDompé Farmaceutici S.p.A602016-12-012020-11-25
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution, Placebo - Retinitis Pigmentosa
Phase 1 / Phase 2CompletedDompé Farmaceutici S.p.A502014-01-012024-04-18
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle - Neurotrophic Keratitis, Keratitis
Phase 1 / Phase 2CompletedDompé Farmaceutici S.p.A1742013-01-012024-04-19
Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers
rhNGF 0.5 µg/mL Sentinel, rhNGF 5 µg/mL Sentinel, rhNGF 20 µg/mL Sentinel - Healthy
Phase 1CompletedDompé Farmaceutici S.p.A742012-07-012024-04-19

Conditions studied

Cone-Rod Dystrophies (1)  ·  Corneal Diseases (1)  ·  Corneal Ulcer (1)  ·  Glaucoma (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Keratitis (1)  ·  Retinitis Pigmentosa (1)

Sponsors

Dompé Farmaceutici S.p.A (5)  ·  Tufts Medical Center (1)

Countries

United States (3)  ·  Italy (2)  ·  United Kingdom (2)  ·  France (1)  ·  Germany (1)  ·  Poland (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Flavio Mantelli, MD, PhD (2)  ·  Ashley Brooks, MBChB (1)  ·  Francesco Sinigaglia, MD (1)  ·  Jeffrey L Goldberg, MD, PhD (1)  ·  Mauro P Ferrari, PharmD (1)  ·  Pedram Hamrah, MD (1)  ·  Pier Adelchi Ruffini, MD (1)  ·  Thierry Kamtchoua, MD (1)

Results publications

PMID 24327173, PMID 26448169, PMID 34780798